[1]郑王彪,郑 超,孙 强.医保药品目录动态调整的国际经验与启示[J].卫生经济研究,2023,40(12):62-67.
　ZHENG Wangbiao,ZHENG Chao,SUN Qiang.International Experience and Enlightenment on the Dynamic Adjustment of Medical Insurance Drug Catalog[J].Journal Press of Health Economics Research,2023,40(12):62-67.
点击复制

医保药品目录动态调整的国际经验与启示
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
40
期数:
2023年12期
页码:
62-67
栏目:
他山之石
出版日期:
2023-11-30

文章信息/Info

Title:
International Experience and Enlightenment on the Dynamic Adjustment of Medical Insurance Drug Catalog
作者:
郑王彪1; 2; 郑 超1; 2; 孙 强1; 2
1.山东大学齐鲁医学院公共卫生学院卫生管理与政策研究中心，山东 济南 250012
2.国家卫生健康委员会卫生经济与政策研究重点实验室（山东大学），山东 济南 250012
Author(s):
ZHENG Wangbiao;  ZHENG Chao;  SUN Qiang
Centre for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan Shandong 250012, China
关键词:
医保药品目录; 动态调整机制; 卫生技术评估; 药品分类管理
Keywords:
medical insurance drug catalog;  dynamic adjustment mechanism;  health technology assessment;  drug classification manag-ement
分类号:
R197.1
文献标志码:
A
摘要:
英国、法国、韩国的医保药品目录调整经验显示，成熟的药品价值评估体系、分类管理机制和风险分担体系发挥了重要作用。我国可以适当借鉴国际经验，创新医保药品目录的动态调整机制，完善药品分类管理体系，依托独立的卫生技术评估机构开展全流程药物评估，以及建立多方参与的风险分担体系，满足人民群众多元化医疗保障需求。
Abstract:
From the experience of adjusting the medical insurance drug catalog in the UK, France, and South Korea, it can be seen that mature drug value evaluation systems, classification management mechanisms, and risk sharing systems have played an important role. By appropriately drawing on international experience, we should innovate the dynamic adjustment mechanism of the medical insurance drug catalog, improve the drug classification management system, rely on independent health technology assessment institutions to conduct whole process drug evaluation, and establish a multi-party risk sharing system, in order to meet the diverse medical security demands of the people.

参考文献/References:

[1] OECD.Health expenditure and financing[EB/OL].[2023-05-26]．https://stats.oecd.org/Index.aspx?DataSetCode.
[2] Guide to the processes of technology appraisal.[EB/OL].(2018-05-30)[2023-05-26]．https://www.nice.org.uk/process/pmg19/chapter/acknowledgements.
[3] Technology appraisal guidance[EB/OL].[2023-05-26]．https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance.
[4] Technology appraisal processes[EB/OL]. (2022-01-01)[2023-05-26]．https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/process.
[5] 姚嘉奇，周挺，管欣，等.英国NICE卫生技术评估介绍及对我国医保目录动态调整的启示[J].中国循证医学杂志，2018，18（9）：984-989.
[6] 李轶.成本-效果阈值在医保准入决策中的应用[J].中国药物经济学，2020，15（9）：30-35.
[7] 谢金平，邵蓉.英国NICE药品卫生技术评估和决策框架体系研究及启示 [J].中国卫生经济，2020，39（12）：114-119.
[8] Interim Process and Methods of the Highly Specialised Technologies Programme Updated to reflect 2017 changes[EB/OL].(2017-04-01)[2023-05-26]．https://www.nice.org.uk/Media/Default/About/what- we-do/NICE-guidance/NICE-highly-specialised-technologies-guidance/HST-interim-methods-process-guide-may-17.
[9] 沈秋欢.药品参考价格制度典型国家创新药品定价与补偿机制[J]. 中国新药杂志，2017，26（14）：1612-1617.
[10] 谢金平，邵蓉.法国卫生技术评估和定价与偿付政策研究及对我国的启示[J].中国医疗保险，2020（8）：65-70.
[11] Doctrine de la commission de la transparence(CT).[EB/OL].[2023-05-26]．https://www.has-sante.fr/upload/docs/application/pdf/2021-03/doctrine_ct.
[12] 郑淇，张方.法国药品定价管理过程与方法介绍[J].中国药业，2014，23（4）：3-6.
[13] Lee H,Kim J.Delisting Policy reform in South Korea:failed or policy change?[J].Value in Health,2012(15):204-212.
[14] 伍琳，陈永法.韩国和德国专利药价格谈判模式比较研究及启示[J].中国卫生政策研究，2015，8（10）：62-67.
[15] 钱然，马爱霞.韩国药品补偿政策及药物经济学应用研究[J].卫生经济研究，2017（2）：46-48.
[16] Yoo S L,Kim D J,Lee S M,et al.Improving patient access to new drugs in South Korea: evaluation of the national drug formulary system[J].International Journal of Environmental Research and Public Health,2019,16(2):288.
[17] 《国家医保局 人力资源社会保障部关于印发〈国家基本医疗保险、工伤保险和生育保险药品目录（2022年）〉的通知》政策解读[EB/OL]. （2023-01-18）[2023-06-18]．http：//www.nhsa.gov.cn/art/2023/1/18/art_105_10081.html.

相似文献/References:

[1]徐 伟,马 丽,高 楠.医保药品目录动态调整机制研究[J].卫生经济研究,2017,(11):51.
[2]林 萍,刘 宝.医疗服务价格动态调整机制探讨[J].卫生经济研究,2019,(08):20.
　LIN Ping,LIU Bao.The Dynamic Adjustment Mechanism of Medical Service Price[J].Journal Press of Health Economics Research,2019,(12):20.
[3]李赛赛,徐 伟,王煜昊,等.创新药物医保目录准入研究[J].卫生经济研究,2019,(10):40.
　LI Sai-sai,XU Wei,WANG Yu-hao,et al.Research on Access to the List of Innovative Medicines[J].Journal Press of Health Economics Research,2019,(12):40.
[4]张远妮,姚奕婷,邹俐爱.医疗服务价格管理权限改革分析[J].卫生经济研究,2021,38(3):17.
　ZHANG Yuan-ni,YAO Yi-ting,ZOU Li-ai.Analysis on Medical Service Price Management Authority Reform[J].Journal Press of Health Economics Research,2021,38(12):17.
[5]谭清立,林岱衡.论医保统筹进程中的医保药品目录管理[J].卫生经济研究,2021,38(3):50.
　TAN Qing-li,LIN Dai-heng.Discussion on the Management of Medical Insurance Drug Catalogue in the Process of Social Pooling for Medical Insurance[J].Journal Press of Health Economics Research,2021,38(12):50.
[6]陈永成,张雯雯,任 翔.深化医疗服务价格改革的背景、特点与思考[J].卫生经济研究,2021,38(11):10.
　CHEN Yong-cheng,ZHANG Wen-wen,REN Xiang.The Background, Characteristics and Thinking of Deepening the Medical Service Price Reform[J].Journal Press of Health Economics Research,2021,38(12):10.
[7]孙 佳.城乡居民医保筹资动态调整机制研究[J].卫生经济研究,2023,40(3):68.
　SUN Jia.The Feasibility Study of the Dynamic Adjustment in Residents' Medical Insurance Financing[J].Journal Press of Health Economics Research,2023,40(12):68.
[8]张明敏,王国平.2021版国家医保药品目录限定支付情况研究[J].卫生经济研究,2023,40(3):72.
　ZHANG Mingmin,WANG Guoping.Study on the Limited Payment of Medical Insurance Drug List 2021[J].Journal Press of Health Economics Research,2023,40(12):72.
[9]孔维政,牟崇婷,于保荣.医用耗材医保准入机制研究[J].卫生经济研究,2023,40(9):19.
　KONG Weizheng,MOU Chongting,YU Baorong.Study on the Medical Insurance Access Mechanism for Medical Consumables[J].Journal Press of Health Economics Research,2023,40(12):19.

更新日期/Last Update: 2023-11-30